These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31232616)

  • 1. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
    Pafili K; Papanas N
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):693-695. PubMed ID: 31232616
    [No Abstract]   [Full Text] [Related]  

  • 2. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 3. SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
    Ferrannini G; Savarese G; Cosentino F
    Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 6. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 7. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects and Safety of Sodium Glucose Cotransporter 2 Inhibitors in Diabetes Patients With Drug-Refractory Advanced Heart Failure.
    Seo Y; Yamamoto M; Machino-Ohtsuka T; Ishizu T; Aonuma K
    Circ J; 2018 Jun; 82(7):1959-1962. PubMed ID: 29695659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):435-447. PubMed ID: 32000956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
    Ren DY; Zhang Y
    Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.
    Coats AJS; Seferović PM
    Eur J Heart Fail; 2019 Mar; 21(3):261-263. PubMed ID: 30884001
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
    Ceylan AF; Ren SY
    Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
    Honigberg MC; Vardeny O; Vaduganathan M
    Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
    [No Abstract]   [Full Text] [Related]  

  • 15. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
    Januzzi J; Ferreira JP; Böhm M; Kaul S; Wanner C; Brueckmann M; Petrie MC; Ofstad AP; Zeller C; George J; Fitchett D; Zannad F
    Eur J Heart Fail; 2019 Mar; 21(3):386-388. PubMed ID: 30767353
    [No Abstract]   [Full Text] [Related]  

  • 16. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?
    Khunti K; Seidu S; Davies MJ
    Diabetes Obes Metab; 2019 Feb; 21(2):207-209. PubMed ID: 30178516
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
    Imprialos K; Stavropoulos K; Papademetriou V
    Heart Fail Clin; 2019 Oct; 15(4):519-530. PubMed ID: 31472887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Badwan OZ; Braghieri L; Skoza W; Agrawal A; Menon V; Tang WHW
    Cleve Clin J Med; 2024 Jan; 91(1):47-51. PubMed ID: 38167393
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
    McKenzie T; Hale GM; Miner A; Colón Colón J; Evins G; Wade J
    Heart Fail Rev; 2024 Mar; 29(2):549-558. PubMed ID: 38300379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.